Adaptimmune Therapeutics PLC (ADAPY)
↓ Download CSV- Sector Manufacturing
- Incorporated X0
- Fiscal year ends Dec 31
In fiscal 2024, Adaptimmune Therapeutics PLC reported revenue of $178.03M, up 195.3% from the prior year. The company ran a net loss, with a net margin of -39.8%. It held $245.96M in total assets against $234.11M in total liabilities.
Key ratios (FY2024)
-38.6%
Operating margin
-39.8%
Net margin
-597.6%
Return on equity
+195.3%
Revenue growth (YoY)
| Metric (FY) | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $178.03M | $60.28M | $27.15M | $6.15M | $3.96M | $1.12M | $59.51M | $37.83M | $14.20M | — |
| Cost of Revenue | $70.0K | — | — | — | — | — | — | — | — | — |
| Operating Income | -$68.76M | -$139.74M | -$163.97M | -$162.25M | -$133.41M | -$139.77M | -$82.36M | -$80.66M | -$72.80M | -$24.64M |
| Net Income | -$70.81M | -$113.87M | -$165.46M | -$158.09M | -$130.09M | -$137.16M | -$95.51M | -$70.14M | -$71.58M | -$22.06M |
| EPS (Diluted) | $-0.05 | $-0.09 | $-0.17 | $-0.17 | $-0.15 | $-0.22 | — | — | — | — |
| Total Assets | $245.96M | $282.62M | $328.92M | $469.55M | $451.14M | $181.54M | $276.74M | $281.15M | $234.51M | $285.82M |
| Total Liabilities | $234.11M | $243.10M | $247.04M | $263.58M | $109.92M | $57.91M | $29.85M | $78.16M | $68.37M | $50.83M |
| Shareholders' Equity | $11.85M | $39.51M | $81.88M | $205.96M | $341.23M | $123.64M | $246.88M | $202.98M | $166.14M | $234.99M |
| Cash & Equivalents | $91.14M | $143.99M | $108.03M | $149.95M | $56.88M | $50.41M | $68.38M | $84.04M | $158.78M | $194.26M |
| Operating Cash Flow | -$73.21M | -$140.88M | -$141.77M | $10.73M | -$53.59M | -$112.51M | -$104.39M | -$54.31M | -$48.17M | -$29.67M |
| Capital Expenditures | $886.0K | $4.68M | $29.50M | $8.57M | $2.34M | $1.59M | $3.91M | $24.64M | $11.51M | $5.08M |
| Shares Outstanding | 1.54B | 1.36B | 987.11M | 928.55M | 928.75M | 631.00M | 627.45M | 562.12M | 424.78M | 424.71M |